ArticleOpen forum infectious diseases2024
Model-Informed Precision Dosing Improves Outcomes in Patients Receiving Vancomycin for Gram-Positive Infections.
Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Precision Dosing of Vancomycin: A Systematic Review of Population Pharmacokinetics Models and Comparative Evaluation of Software Tools.Clinical pharmacokinetics · 2026Pooled it
- Big Data Bayesian Truths: No Vancomycin Trough Concentration Target Is Sufficiently Precise for Safety or Efficacy.Open forum infectious diseases · 2025Trial
- Impact of adsorptive CRRT membranes on vancomycin pharmacokinetics in critically ill patients.Renal failure · 2026Review
- A qualitative process evaluation of a clinical trial on bedside model-informed precision dosing of vancomycin in critically ill children.International journal of clinical pharmacy · 2026Article
- Safety Monitoring of High-Risk Antibiotics Using Artificial Intelligence: A Narrative Review with Focus on Real-World Evidence.Life (Basel, Switzerland) · 2026Review
- Population Pharmacokinetics of Voriconazole in Patients Receiving Extracorporeal Membrane Oxygenation.Pharmaceutical research · 2026Article
- Intra-Individual Variability of Vancomycin Trough Concentrations Before and After Implementation of a Standardized Operating Procedure in Orthopedic Inpatients.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical Use of Bayesian Model-Informed Precision Dosing in Routine Practice: A Focused Systematic Review.Journal of clinical medicine · 2026Review
- Optimizing Vancomycin Dosing in Continuous Renal Replacement Therapy: A Systematic Review of Population Pharmacokinetic Studies in Adult Critically Ill Patients.Pharmaceutics · 2026Review
- Pharmacokinetics and Customized Dosing of Vancomycin in Adult Patients With Hematological Malignancies: Status, Challenges, and Opportunities.Pharmacology research & perspectives · 2026Review
- Artificial intelligence in optimizing antimicrobial therapy for gastro-renal disorders.Frontiers in cellular and infection microbiology · 2026Review
- Impact of rapid molecular testing on clinical outcomes for methicillin-susceptibleAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Guidance for External Evaluation and Selection of Population Pharmacokinetic Models for Precision Dosing.Clinical pharmacokinetics · 2026Review
- Population Pharmacokinetics and Clinical Application of Vancomycin in Critically Ill Adults: A NONMEM-Based Review.Drug design, development and therapy · 2026Review
- A Retrospective Within-Subjects Analysis of Vancomycin Bayesian Modeling With Pre-steady-State vs Steady-State Concentrations.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2025Article
- Implementing a Standard Operating Procedure Is Associated with Improved Vancomycin Target Attainment in Bone and Joint Infections: A Pre-Post Study.Antibiotics (Basel, Switzerland) · 2025Article
- Predictive Performance of Bayesian Dosing Software for Vancomycin in Intensive Care Unit Patients.Therapeutic drug monitoring · 2025Article
- [Free online software tools for precision dosing of vancomycin, and other drugs]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2025Review
- Editorial: The impact of pharmacokinetics and pharmacodynamics on antimicrobial stewardship.Frontiers in cellular and infection microbiology · 2025Article
- Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients.Critical care explorations · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Consensus guidelines for dosing and monitoring of vancomycin recommend collection of 2 serum concentrations to estimate an area under the curve/minimum inhibitory concentration ratio (AUC/MIC). Use of Bayesian software for AUC estimation and model-informed precision dosing (MIPD) enables pre-steady state therapeutic drug monitoring using a single serum concentration; however, data supporting this approach are limited. Methods: Adult patients with culture-proven gram-positive infections treated with vancomycin ≥72 hours receiving either trough-guided or AUC-guided therapy were included in this retrospective study. AUC-guided therapy was provided using MIPD and single-concentration monitoring. Treatment success, vancomycin-associated acute kidney injury (VA-AKI), and inpatient mortality were compared using a desirability of outcome ranking analysis. The most desirable outcome was survival with treatment success and no VA-AKI, and the least desirable outcome was death. Results: The study population (N = 300) was comprised of an equal number of patients receiving AUC-guided or trough-guided therapy. More patients experienced the most desirable outcome in the AUC-guided group compared to the trough-guided group (58.7% vs 46.7%, Conclusions: AUC-guided vancomycin therapy using MIPD and single-concentration monitoring improved outcomes in patients with culture-proven gram-positive infections. Safety was improved with reduced incidence of VA-AKI, and no concerns for reduced efficacy were observed. Moreover, MIPD allowed for earlier assessment of AUC target attainment and greater flexibility in the collection of serum vancomycin concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.